Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
UB-221 in Chronic Spontaneous Urticaria
NCT04175704Phase 1Not yet recruiting
- Sponsor
- United BioPharma
- Start
- Dec 2023
- Primary completion
- Nov 2024
- Modality
- Monoclonal Antibodies
01
Overview
Phase 1, randomised, single-blind trial of ub-221 in chronic spontaneous urticaria (CSU) (4 cohorts), sponsored by United BioPharma. Primary endpoint: Adverse events and serious adverse events at 99 days. Planned start Dec 2023; status: not yet recruiting.
02
Drugs
ub-221
03
Conditions
chronic spontaneous urticaria (CSU)
Beyond the preview
Go deeper on NCT04175704.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04175704.